Caffeine: Physiological and pharmacologic aspects;Caffein: Fysiologiske og farmakologiske aspekter

Ugeskrift for Laeger

Volumn 166, Issue 22, 2004, Pages 2138-2142

  Nørager, Charlotte Buchard ^a,b   Jensen, Martin Bach ^b   Madsen, Mogens Rørbæk ^b  

^a Århus Universitetshospital ^*  (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE;

BICYCLE; COFFEE; COMPETITION; DOPING; DRUG MECHANISM; ENDURANCE; FATIGUE; FOOD; HEADACHE; HEART PALPITATION; RESTLESSNESS; REVIEW; RUNNING; SPORT; SWIMMING; TRAINING; WITHDRAWAL SYNDROME;

EID: 2942748192     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Nehlig A, Debry G. Caffeine and sports activity: a review. Int J Sports Med 1994;15:215-23.
2. Sinclair CJ, Geiger JD. Caffeine use in sports. J Sports Med Phys Fitness 2000;40:71-9.
3. Wagner JC. Enhancement of athletic performance with drugs. Sports Med 1991;12:250-65.
4. Kovacs EM, Stegen JHCH, Brouns F. Effect of caffeinated drinks on substrate metabolism, caffeine excretion, and performance. J Appl Physiol 1998;85: 709-15.
5. Kovacs EM, Martin AM, Brouns F. The effect of ad libitum ingestion of a caffeinated carbohydrate-electrolyte solution on urinary caffeine concentration after 4 hours of endurance exercise. Int J Sports Med 2002;23:237-41.
6. Durrant KL. Known and hidden sources of caffeine in drug, food, and natural products. J Am Pharm Assoc (Wash) 2002;42:625-37.
7. Chou TM, Benowitz NL. Caffeine and coffee: effects on health and cardiovascular disease. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1994;109:173-89.
8. Arnaud MJ. The pharmacology of caffeine. Prog Drug Res 1987;31:273-313.
9. Curatolo PW, Robertson D. The health consequences of caffeine. Ann Intern Med 1983;98(5 Pt 1):641-53.
10. Graham TE. Caffeine and exercise: metabolism, endurance and performance. Sports Med 2001;31:785-807.
11. Grab FL, Reinstein JA. Determination of caffeine in plasma by gas chromatography. J Pharm Sci 1968;57:1703-6.
12. Mumford GK, Benowitz NL, Evans SM et al. Absorption rate of methylxanthines following capsules, cola and chocolate. Eur J Clin Pharmacol 1996; 51:319-25.
13. Wang Y, Lau CE. Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. Pharmacol Biochem Behav 1998;60:271-8.
14. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
15. Agundez JA, Gallardo L, Martinez C et al. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics 1998;8:251-8.
16. Goasduff T, Dreano Y, Guillois B et al. Induction of liver and kidney CYP1A1/ 1A2 by caffeine in rat. Biochem Pharmacol 1996;52:1915-9.
17. Graham TE, Rush JW, van Soeren MH. Caffeine and exercise: metabolism and performance. Can J Appl Physiol 1994;19:111-38.
18. Raguso CA, Coggan AR, Sidossis LS et al. Effect of theophylline on substrate metabolism during exercise. Metabolism 1996;45:1153-60.
19. Le Marchand L, Franke AA, Custer L et al. Lifestyfe and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma futein and alpha-tocopherol. Pharmacogenetics 1997;7:11-9.
20. Ou-Yang DS, Huang SL, Wang W et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000;49:145-51.
21. Rasmussen BB, Brix TH, Kyvik KO et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002;12:473-8.
22. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39: 127-53.
23. Swanson JA, Lee JW, Hopp JW et al. The impact of caffeine use on tobacco cessation and withdrawal. Addict Behav 1997;22(:55-68.
24. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13:1561-8.
25. Bonati M, Latini R, Tognoni G et al. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev 1984;15:1355-83.
26. Kalow W. Variability of caffeine metabolism in humans. Arzneimittelforschung 1985;35:319-24.
27. Duthel JM, Vallon JJ, Martin G et al. Caffeine and sport: role of physical exercise upon elimination. Med Sci Sports Exerc 1991;23:980-5.
28. Kovacs EM, Stegen JHCH, Brouns F. Effect of caffeinated drinks on substrate metabolism, caffeine excretion, and performance. J Appl Physiol 1998;85: 709-15.
29. Bruce CR, Anderson ME, Fraser SF et al. Enhancement of 2000-m rowing performance after caffeine ingestion. Med Sci Sports Exerc 2000;32:1958-63.
30. Pasman WJ, van Baak MA, Jeukendrup AE et al. The effect of different dosages of caffeine on endurance performance time. Int J Sports Med 1995; 16:225-30.
31. Graham TE, Spriet LL. Performance and metabolic responses to a high caffeine dose during prolonged exercise. J Appl Physiol 1991;71:2292-8.
32. Costill DL, Dalsky GP, Fink WJ. Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports 1978;10:155-8.
33. Chesley A, Hultman E, Spriet LL. Effects of epinephrine infusion on muscle glycogenolysis during intense aerobic exercise. Am J Physiol 1995;268 (1 Pt 1):E127-34.
34. Chesley A, Howlett RA, Heigenhauser GJ et al. Regulation of muscle glycogenolytic flux during intense aerobic exercise after caffeine ingestion. Am J Physiol 1998;275(2 Pt 2):R596-603.
35. Van Soeren M, Mohr T, Kjaer M et al. Acute effects of caffeine ingestion at rest in humans with impaired epinephrine responses. J Appl Physiol 1996; 80:999-1005.
36. Ogawa Y. Role of ryanodine receptors. Crit Rev Biochem Mol Biol 1994;29:229-74.
37. Shum S, Seale C, Hathaway D et al. Acute caffeine ingestion fatalities: management issues. Vet Hum Toxicol 1997;39:228-30.
38. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995;35:581-606.
39. Sattin A, Rall TW. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′, 5′-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 1970;6:13-23.
40. Green RM, Stiles GL. Chronic caffeine ingestion sensitizes the A1 adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest 1986; 77:222-7.